Both US and EU regulators recognize the important potential benefits and value of decentralized clinical trials (DCTs) and are keen to support such studies. Their respective guidelines on DCTs - issued just five months apart - are largely similar but have some notable differences.
The US Food and Drug Administration published its draft DCT guideline in May, with stakeholder comments being accepted until 1...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?